# MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

Source: https://onco.cc/trials/nct06097728/  
OnCo record `nct06097728` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pemetrexed, Carboplatin, Cisplatin in mesothelioma, run by AstraZeneca, active and no longer recruiting.

## Summary

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma is a phase 3 interventional study registered as NCT06097728 by AstraZeneca, with 863 participants enrolled, started 2023-11-09 and due to reach its primary completion in 2028-11-16. Interventions recorded: Volrustomig, Pemetrexed, Carboplatin, Cisplatin, Nivolumab. Conditions listed: Unresectable Pleural Mesothelioma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06097728
- Phase: 3
- Setting: A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (eVOLVE-Meso)
- Sponsor: AstraZeneca
- Enrolled: 863

## Sources

- ClinicalTrials.gov NCT06097728: https://clinicaltrials.gov/study/NCT06097728

## Connected records

- cancers: [Mesothelioma](https://onco.cc/cancers/mesothelioma/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06097728.json